Does Insurance Cover Wegovy & Zepbound? (2026)

See if you qualify in 5 minutes →
5-minute questionnaire · reviewed by a licensed clinician · The Nouri Promise: full refund if not satisfied in 30 days, on 3-month and 6-month plans · cancel anytime

Does Insurance Cover Wegovy and Zepbound? At a Glance

Coverage type	Weight-loss GLP-1 (Wegovy / Zepbound)	Notes
Employer / commercial plan	Sometimes — ~40% exclude weight-loss drugs	Prior auth nearly universal where covered; check your formulary
Diabetes GLP-1s (Ozempic / Mounjaro)	Widely covered for type 2 diabetes	Same active ingredients, different FDA indication; not covered off-label for weight loss
Medicare Part D	Not for weight loss alone	$50/mo GLP-1 Bridge from Jul 1, 2026 (eligibility applies); Wegovy covered for CV risk; Zepbound for sleep apnea
Medicaid	Varies — ~13 states cover for obesity	All states cover diabetes GLP-1s; obesity coverage is state-by-state
Manufacturer self-pay (brand)	~$199/mo (Wegovy NovoCare) or $299–$449/mo (Zepbound LillyDirect vials)	As of June 2026, per manufacturer sites — verify before acting
Compounded GLP-1 (cash-pay)	~$99–$399/month at most telehealth programs	Not FDA-approved; not therapeutically equivalent to brand-name drugs

Brand prices reflect publicly available information as of June 2026 and change frequently — verify with the manufacturer before deciding. For a full breakdown, see the GLP-1 cost guide (2026).

Why insurance coverage for weight-loss GLP-1s is so inconsistent

Insurance coverage for weight-loss GLP-1s like Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) is governed by a complex, employer-driven system — and in 2026, coverage is not keeping pace with prescribing. Here is why.

The employer-plan decision

Most Americans with commercial insurance are covered by employer-sponsored plans. Employers — not just insurance carriers — decide whether to include weight-loss drug benefits. A KFF analysis found that coverage is expanding slowly, but as of 2025–2026 a substantial share of employer plans — roughly 40%, per available employer-survey data — still exclude GLP-1s for weight management. Large, self-insured employers are somewhat more likely to cover them; small and mid-size employers often follow their insurer's standard formulary, which tends toward exclusion.

The "same molecule, different coverage" problem

One of the most confusing aspects of GLP-1 coverage: the same active ingredient may be covered in one context and denied in another. Ozempic (semaglutide, lower-dose formulation for type 2 diabetes) and Rybelsus (oral semaglutide) are widely covered for diabetes across commercial and Medicare Part D plans. Wegovy — semaglutide at a higher dose, FDA-approved for weight management — is frequently excluded, restricted, or subject to strict prior authorization when prescribed for weight loss. The same pattern holds for tirzepatide: Mounjaro (diabetes indication) is broadly covered; Zepbound (weight-loss indication) is much more restricted.

Pharmacy benefit manager formulary shifts

Pharmacy benefit managers (PBMs) negotiate formulary placement and drug pricing. In 2024–2025, at least one major PBM removed Zepbound from its preferred tier in favor of Wegovy — meaning a patient's plan could face higher cost-sharing or a new prior-authorization hurdle for Zepbound where none had existed before. These formulary decisions shift periodically. Verify your plan's current formulary before assuming coverage status.

Medicare and GLP-1s: the new $50/month Bridge — and what Medicare can cover now

Medicare has been statutorily barred from covering weight-loss drugs since the Medicare Modernization Act of 2003 — a restriction originally intended to limit drug spending but increasingly contested as GLP-1s have proven to be more than weight-loss agents.

The Medicare GLP-1 Bridge ($50/month, starting July 1, 2026)

Starting July 1, 2026, a time-limited CMS demonstration — the Medicare GLP-1 Bridge — gives eligible Part D members a flat $50/month copay for certain weight-loss GLP-1s. Eligibility generally requires BMI ≥27 with a qualifying condition, or BMI ≥35 automatically. Importantly, these $50 copays do not count toward your deductible or out-of-pocket maximum, and this is a demonstration program — not a permanent benefit. Confirm current eligibility criteria and participating drugs directly on the CMS Medicare GLP-1 Bridge page before acting.

Medicare coverage for specific non-weight-loss indications

Two narrower exceptions to the Medicare weight-loss drug bar are now in effect:

• Wegovy for cardiovascular risk reduction: In early 2024, the FDA approved Wegovy for reducing the risk of serious cardiovascular events in adults with established cardiovascular disease and overweight or obesity — based on the SELECT trial (Lincoff et al., NEJM 2023), which was research on the branded molecule semaglutide 2.4 mg, not on compounded semaglutide. Some Medicare plans may now cover Wegovy for this specific cardiovascular indication; check your individual plan.
• Zepbound for obstructive sleep apnea: The FDA approved Zepbound for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. This indication may allow some Medicare plans to cover it if you have a documented OSA diagnosis. Confirm with your physician and plan.

These exceptions are indication-specific and plan-dependent. They do not extend to weight management coverage more broadly.

Prior authorization: what most plans require

When a plan does cover Wegovy or Zepbound for weight loss, prior authorization (PA) is almost universally required. An industry survey cited by GoodRx found approximately 88% of covered patients face prior authorization. What PA typically involves:

• BMI threshold: Most plans require BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity — hypertension, type 2 diabetes, dyslipidemia, sleep apnea, or cardiovascular disease. The NIDDK's clinical guidance on prescription weight-loss medications describes the standard criteria used in practice.
• Documented treatment history: Many plans require documentation of a prior lifestyle intervention (diet and exercise) — typically at least 3 to 6 months. A letter from a primary care provider or specialist supporting the prescription strengthens the submission.
• Step therapy: Some plans require trying (and documenting failure of) a lower-cost intervention first — for example, phentermine/topiramate or naltrexone/bupropion — before approving a GLP-1.
• Clinical documentation: The prescribing physician submits clinical notes, the patient's weight history, and the relevant diagnosis code. Incomplete documentation is the most common reason for an initial PA denial.

If your PA is denied, a formal peer-to-peer review — where your physician speaks directly with the plan's medical director — can reverse a denial, particularly when clinical documentation is thorough. You also have the right to a formal appeal. See how to get a GLP-1 covered by insurance for a step-by-step walkthrough of the appeal process.

Medicaid: the state-by-state patchwork

Medicaid coverage for weight-loss GLP-1s is more restricted than commercial coverage and highly variable by state. As of 2026, approximately 13 states cover GLP-1s for obesity treatment under Medicaid — a figure tracked by health-policy organizations and subject to ongoing state budget decisions. All 50 states cover diabetes GLP-1s under Medicaid (Ozempic, Mounjaro), but obesity coverage is a distinct benefit that states may choose to include or exclude in their Medicaid drug formularies.

Medicaid expansion status under the Affordable Care Act is separate from GLP-1 coverage: an ACA expansion state is not necessarily one that covers GLP-1s for weight management. Check your state's Medicaid formulary directly, or ask your prescribing physician's office to verify coverage before requesting a prescription.

Manufacturer savings programs when you are partially covered

Even if your plan covers Wegovy or Zepbound, significant cost-sharing can remain. Both manufacturers offer programs to reduce out-of-pocket costs for commercially insured patients:

• Wegovy (NovoCare): Novo Nordisk has offered an introductory self-pay price of approximately $199/month for certain patients and a separate copay savings program for those with commercial insurance. As of June 2026, per NovoCare's website — verify current terms and eligibility before acting, as these programs can change or expire.
• Zepbound (LillyDirect): Eli Lilly's direct-to-patient program offers Zepbound single-dose vials at self-pay prices of approximately $299/month (2.5 mg or 5 mg) to $449/month (higher doses) as of June 2026, per LillyDirect's site. A separate copay assistance card is available for commercially insured patients. Verify current terms and eligibility.

These programs are generally not available to Medicare or Medicaid beneficiaries. Confirm eligibility on the manufacturer's site before assuming you qualify. For a full side-by-side of brand and compounded GLP-1 costs, see compounded vs. brand GLP-1 cost.

When your plan denies coverage: what to do next

A first denial is not necessarily final. In order:

1. Get the denial in writing. Your plan must provide a written explanation citing the specific criteria not met. Read it carefully — the denial language tells you exactly what to address.
2. Request a peer-to-peer review. Your physician can speak directly with the plan's medical director to present your clinical case. This is most effective when the initial denial was for incomplete documentation.
3. File a formal appeal. Under the ACA, you have the right to appeal coverage and prior-authorization denials. Include clinical notes, weight history, and any comorbidities. For employer-sponsored plans subject to ERISA, you also have the right to external review after exhausting the internal process.
4. Request a formulary exception. If Wegovy or Zepbound is excluded from your plan's formulary, a formulary exception (supported by a medical necessity letter) is a separate channel from the PA appeal.
5. Explore self-pay options if insurance coverage is genuinely unavailable or cost-sharing remains prohibitive (see below).

For the full appeal guide: how to get a GLP-1 covered by insurance.

If insurance won't cover it: compounded GLP-1s as a self-pay option

When brand-name GLP-1s are excluded or the out-of-pocket cost remains prohibitive, compounded GLP-1 medications are a separate, cash-pay pathway. Compounded semaglutide and tirzepatide are prepared by state-licensed 503A compounding pharmacies and prescribed by licensed physicians following individual clinical review.

Important: Compounded GLP-1 medications are not FDA-approved and are not the same as, or therapeutically equivalent to, the brand-name drugs (Wegovy®, Ozempic®, Zepbound®, Mounjaro®). They are patient-specific formulations, prescribed only when clinically appropriate. The FDA's human drug compounding guidance explains the legal framework governing 503A pharmacy compounding.

Self-pay telehealth programs offering compounded GLP-1s typically range from approximately $99 to $399/month, depending on the program structure and what is included. Some programs quote a low headline price but add a separate monthly membership fee on top — compare the all-in monthly cost when evaluating options. For a data-based comparison across programs, see the GLP-1 telehealth pricing dataset (June 2026) and the cheapest GLP-1 cost comparison guide.

Also worth noting: a lawfully prescribed compounded GLP-1 may be eligible for HSA/FSA reimbursement — see Can You Use HSA/FSA for a GLP-1? for the hedged guidance and what documentation you need.

Where Nouri fits on cost

Nouri's The Program includes compounded semaglutide at $120/month on the 6-month plan ($720 every 6 months), or $145/month on the 3-month plan ($435 every 3 months). Compounded tirzepatide is $175/month on the 6-month plan ($1,050 every 6 months), or $199/month on the 3-month plan ($597 every 3 months). One all-in price — any dose, same price — with a personalized nutrition plan, a movement plan, and clinician-guided care included. No membership fee added on top.

When comparing programs, watch for "$99/month" or similar teaser pricing that layers a separate $49–$79 monthly membership fee on top. The all-in monthly number is what matters. For a structured pricing comparison across telehealth programs, see the GLP-1 cost guide for 2026 and the GLP-1 telehealth pricing dataset.

Nouri is available in all 50 states. Medication is prescribed only when clinically appropriate after a licensed physician reviews your intake — not all applicants qualify. Compounded medications are prepared by Jungle Jim's Pharmacy (a state-licensed 503A compounding pharmacy in Fairfield, OH) and VialsRX. Nouri is LegitScript-certified.

Compounded GLP-1 medications are not FDA-approved and are not the same as, or therapeutically equivalent to, the brand-name drugs.

Start your 5-minute assessment →
Reviewed by a licensed clinician · The Nouri Promise: full refund if not satisfied in 30 days, on 3-month and 6-month plans · cancel anytime

Related cost guides

• GLP-1 Cost in 2026: Complete Guide
• How to Get a GLP-1 Covered by Insurance
• Wegovy Cost Without Insurance (2026)
• Zepbound Cost Without Insurance (2026)
• Compounded vs. Brand GLP-1 Cost Comparison
• Can You Use HSA/FSA for a GLP-1?
• Cheapest Way to Get a GLP-1 (Cost Comparison)

Frequently asked questions

Does insurance cover Wegovy for weight loss?

Sometimes, but often not — roughly 40% of employer plans exclude weight-loss drugs, and most that do cover Wegovy require prior authorization (typically BMI ≥30, or ≥27 with a related condition). Coverage is entirely plan-specific; the same insurance carrier may cover GLP-1s on one employer's plan but exclude them on another's. Check your formulary first.

Does Medicare cover Zepbound or Wegovy?

Not for weight loss alone — a longstanding statutory restriction. However, Medicare may now cover Wegovy for cardiovascular risk reduction (an FDA-approved indication since 2024) and Zepbound for obstructive sleep apnea, if you have those diagnosed conditions. A new $50/month Medicare GLP-1 Bridge starts July 1, 2026 for eligible members — verify eligibility and participating drugs on the CMS website.

Why won't my insurance cover Wegovy?

Most plans classify weight-loss drugs separately from other chronic-disease treatments, and many exclude them entirely. Even within the same molecule: Ozempic (lower-dose semaglutide for diabetes) is widely covered, while Wegovy (higher-dose semaglutide for weight management) often is not. Prior authorization criteria, step therapy requirements, and formulary decisions all play a role.

What is the Medicare GLP-1 Bridge $50/month program?

A time-limited CMS demonstration starting July 1, 2026 that gives eligible Medicare Part D members a flat $50/month copay for certain weight-loss GLP-1s (generally BMI ≥27 with a qualifying condition, or BMI ≥35 automatically). The $50 copays do not count toward your deductible or out-of-pocket maximum. This is a demonstration — not a permanent benefit — so verify current details on the CMS website before acting.

Which insurance companies cover weight-loss drugs?

Coverage depends on your specific plan, not just the insurer's name. Large, self-insured employers are more likely to include a weight-management GLP-1 benefit. Even within a single carrier, two employers on the same platform may have different benefit designs. The only reliable way to know is to check your plan's formulary or call member services directly.

Does insurance cover Ozempic?

Ozempic (semaglutide injection) is widely covered for type 2 diabetes across commercial and Medicare Part D plans — much more broadly than the weight-loss versions. It is generally not covered when prescribed off-label for weight management alone. If your plan covers Ozempic for diabetes but not Wegovy for weight loss, that is typical: they are different FDA-approved indications even though the active ingredient is the same molecule.

Do I need prior authorization for Wegovy or Zepbound?

Almost always, if your plan covers them at all. About 88% of covered patients face prior authorization, typically requiring BMI ≥30 (or ≥27 with a comorbidity), clinical documentation of weight-related conditions, and sometimes documented prior lifestyle intervention. Incomplete documentation is the most common reason for initial denial — a peer-to-peer review between your physician and the plan's medical director can often resolve it.

Sources & references

1. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023. — Research on semaglutide 2.4 mg (Wegovy), the branded molecule; not research on compounded semaglutide.
2. FDA: Human Drug Compounding — regulatory framework for 503A/503B compounding pharmacies.
3. NIDDK: Prescription Medications to Treat Overweight and Obesity — standard eligibility criteria and clinical guidance on weight-loss medications.
4. CMS: Medicare GLP-1 Bridge ($50/month access, July 2026)
5. KFF: Medicare and Medicaid GLP-1 coverage analysis
6. GoodRx: GLP-1 insurance coverage (2026)
7. Wegovy self-pay & NovoCare savings program — as of June 2026; verify current terms.
8. Zepbound LillyDirect self-pay vials — as of June 2026; verify current terms.
9. Nouri: GLP-1 telehealth pricing dataset (June 2026) — structured price comparison across telehealth programs.

Medically reviewed by Amber Patel, MD. Nouri editorial content is reviewed by licensed clinicians and updated as pricing, formulary decisions, and guidance change.

Prices and coverage described here reflect publicly available information as of June 2026 and change frequently — verify current figures with the manufacturer, your pharmacy, your insurer, and (for HSA/FSA or tax questions) a qualified tax professional before making decisions. This is general educational information, not medical, financial, or tax advice. Ozempic®, Wegovy®, and Rybelsus® are registered trademarks of Novo Nordisk A/S; Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Nouri is not affiliated with, endorsed by, or sponsored by these companies. Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as, or therapeutically equivalent to, the brand-name drugs. Compounded medications are prescribed only when clinically appropriate after review by a licensed provider; not all applicants qualify.